Nifty Pharma News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Nifty Pharma from all sources in a single place.

Load latest

Glenmark Pharmaceuticals Ltd.

12 Mar 2025

1533.55

0.90%

Glenmark launches Empagliflozin for diabetes in India under Glempa brand

Business Standard

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm has launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'?Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk. Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus. Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation. "The launch of Glempa range ..

Glenmark Pharmaceuticals Ltd. is trading above all available SMAs

Zydus Lifesciences Ltd.

12 Mar 2025

894.30

0.40%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Zydus receives final approval from USFDA for Methenamine Hippurate Tablets USP, 1 gram.

pdf

Alkem Laboratories Ltd.

12 Mar 2025

4911.40

-0.98%

Alkem launches low-cost diabetes drug in Indian market

Business Line

The company is introducing several combination therapies including Empanorm L (empagliflozin and linagliptin), Empanorm Duo and Alsita E (empagliflozin and sitagliptin), and Empanorm M (empagliflozin and metformin)

Number of FII/FPI investors increased from 334 to 524 in Dec 2024 qtr.

Glenmark Pharmaceuticals Ltd.

12 Mar 2025

1533.55

0.90%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Glenmark Pharma Expands Cardiometabolic Portfolio with the Launch of Empagliflozin and its Fixed - Drug Combinations in India

pdf

Alkem Laboratories Ltd.

12 Mar 2025

4911.40

-0.98%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

This is to inform you that the Company launches generic empagliflozin and its combinations in India under the brand name "Empanorm". A press release in this regard is enclosed herewith. Kindly take the same on record.

pdf

Gland Pharma Ltd.

11 Mar 2025

1606.40

0.10%

Company Update

Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Investor Call Intimation

pdf

Aurobindo Pharma Ltd.

11 Mar 2025

1160.60

-0.31%

Company Update

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of Investor conference arranged by Antique Stock Broking to be held on March 19, 2025

pdf

Zydus Lifesciences Ltd.

11 Mar 2025

894.30

0.40%

Investor Presentation

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Investor presentation

pdf

Sun Pharmaceutical Industries Ltd.

11 Mar 2025

1711.55

-1.15%

SAST

Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) …

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 11, 2025 for Raksha Valia

pdf

Lupin Ltd.

11 Mar 2025

2011.35

-0.37%

Trump's tariff threat takes the sheen off Lupin's product launches

livemint

A big dampener to Lupin's plans would be the potential imposition of tariff on pharma products by the Trump government. However, the management expressed hope of an exemption for the pharma sector due to the risk of a shortage.

Lupin Ltd. has gained 25.71% in the last 1 Year

No results found

Is Nifty Pharma worth buying?

303 Votes:

Buy 79.21%

Sell 11.55%

Hold 9.24%

Nifty Pharma PB	5.2
Nifty Pharma PE	31.9
Nifty Pharma DIV	0.7
Nifty Pharma EPS	666.5